Inspire Medical Systems, Inc. (NYSE:INSP) Shares Purchased by Voya Investment Management LLC

Voya Investment Management LLC increased its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 1.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 156,575 shares of the company's stock after purchasing an additional 2,639 shares during the period. Voya Investment Management LLC owned approximately 0.52% of Inspire Medical Systems worth $29,026,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in INSP. TimesSquare Capital Management LLC purchased a new position in Inspire Medical Systems in the 4th quarter valued at approximately $80,419,000. Marshall Wace LLP boosted its position in Inspire Medical Systems by 1,775.3% in the 4th quarter. Marshall Wace LLP now owns 277,131 shares of the company's stock valued at $51,375,000 after buying an additional 262,353 shares during the period. Raymond James Financial Inc. purchased a new position in Inspire Medical Systems in the 4th quarter valued at approximately $47,604,000. Riverbridge Partners LLC acquired a new stake in shares of Inspire Medical Systems in the 4th quarter valued at $26,342,000. Finally, Principal Financial Group Inc. raised its holdings in shares of Inspire Medical Systems by 3,812.6% in the 3rd quarter. Principal Financial Group Inc. now owns 141,089 shares of the company's stock valued at $29,777,000 after purchasing an additional 137,483 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company's stock.

Insider Buying and Selling at Inspire Medical Systems

In other news, CTO John Rondoni sold 583 shares of Inspire Medical Systems stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the sale, the chief technology officer now owns 10,424 shares of the company's stock, valued at $1,777,187.76. The trade was a 5.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Randy Ban sold 25,584 shares of Inspire Medical Systems stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the completion of the sale, the insider now directly owns 7,259 shares in the company, valued at approximately $1,332,026.50. The trade was a 77.90 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by company insiders.

Inspire Medical Systems Stock Performance

NYSE INSP traded up $1.67 during trading on Tuesday, reaching $159.78. The company's stock had a trading volume of 400,952 shares, compared to its average volume of 582,240. The firm has a market cap of $4.76 billion, a price-to-earnings ratio of 92.36, a P/E/G ratio of 2.86 and a beta of 1.39. Inspire Medical Systems, Inc. has a twelve month low of $123.00 and a twelve month high of $257.40. The business's fifty day moving average price is $162.45 and its 200-day moving average price is $180.71.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. As a group, sell-side analysts forecast that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Morgan Stanley reduced their price objective on shares of Inspire Medical Systems from $230.00 to $220.00 and set an "overweight" rating on the stock in a report on Tuesday, February 11th. KeyCorp reduced their price objective on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating on the stock in a report on Monday, April 21st. Stifel Nicolaus reduced their price objective on shares of Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a report on Monday, April 21st. Royal Bank of Canada reduced their price objective on shares of Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating on the stock in a report on Tuesday, April 15th. Finally, Truist Financial reduced their price objective on shares of Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating on the stock in a report on Tuesday, February 11th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Inspire Medical Systems presently has a consensus rating of "Moderate Buy" and an average price target of $218.90.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.